These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The spectrum of bone disease in end-stage renal failure--an evolving disorder. Sherrard DJ; Hercz G; Pei Y; Maloney NA; Greenwood C; Manuel A; Saiphoo C; Fenton SS; Segre GV Kidney Int; 1993 Feb; 43(2):436-42. PubMed ID: 8441240 [TBL] [Abstract][Full Text] [Related]
23. [Role of aluminium and magnesium effects on initiation and promotion of renal osteodystrophy in patients with chronic renal failure]. Nakamrua M; Sato N; Tsukamoto Y; Marumo F; Iwanami S Nihon Jinzo Gakkai Shi; 1986 Apr; 28(4):421-8. PubMed ID: 3747253 [No Abstract] [Full Text] [Related]
24. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients]. Nakazawa R Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035 [TBL] [Abstract][Full Text] [Related]
25. Fluoride and dialysis osteodystrophy: results of a double-blind study. Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422 [No Abstract] [Full Text] [Related]
26. Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients. Tzamaloukas AH Med Clin North Am; 1990 Jul; 74(4):961-74. PubMed ID: 2195265 [TBL] [Abstract][Full Text] [Related]
34. Role of phosphate depletion and high dialysate calcium in controlling dialytic renal osteodystrophy. Goldsmith RS; Johnson WJ Kidney Int; 1973 Aug; 4(2):154-60. PubMed ID: 4744973 [No Abstract] [Full Text] [Related]
35. Clearance of aluminum by hemodialysis: effect of desferrioxamine. Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984 [No Abstract] [Full Text] [Related]
36. Detection of subtle aluminum-related renal osteodystrophy. Romanski SA; McCarthy JT; Kluge K; Fitzpatrick LA Mayo Clin Proc; 1993 May; 68(5):419-26. PubMed ID: 7683072 [TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study. De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364 [TBL] [Abstract][Full Text] [Related]
38. The use of desferrioximine in dialysis-associated aluminium disease. Ackrill P; Day JP Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177 [No Abstract] [Full Text] [Related]
39. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients]. Goto S; Fukagawa M Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657 [TBL] [Abstract][Full Text] [Related]
40. [Pathophysiology and treatment of renal osteodystrophy]. Ionova D Vutr Boles; 1985; 24(6):23-9. PubMed ID: 3913143 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]